Scholars Central

Conference abstract

Successfully meeting the regulatory challenges of abuse/ dependence liability evaluation in the development of new centrally-acting drugs

Authors: David Heal

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

T he growing problem of the recreational abuse of prescription pharmaceuticals combined with an increasing awareness of drug withdrawal eff ects have prompted regulatory agencies to place a greater emphasis on abuse/dependence liability assessment for new CNS drug candidates. From the Sponsor?s perspective, the classifi cation of a new CNS pharmaceutical as a Controlled Drug, particularly if it is placed in a high Schedule, will substantially impact on the drug?s market competitiveness and may also impair its distribution and be a barrier to prescribing. Th e mandatory abuse/dependence assessment package involves both preclinical and clinical evaluations. Th e programme needs to determin e whether the subjective eff ects of the compound resemble those of known substances of abuse, whether experience of the drug induces craving (reinforcement), and fi nally, whether tolerance and/or physical dependence occurs when the compound is administered for prolonged periods. Various preclinical testing procedures will be described with examples to illustrate their strengths and weaknesses. A major complicating factor in abuse/dependence testing is that the evaluation programmes and reporting procedures required by European Medicines Agency (EMA) and Food and Drugs Administration (FDA)/ Controlled Substances Staff (CSS) are substantially diff erent. For example, the determination of abuse liability in drug experienced human volunteers is considered to be critical evidence by CSS, but EMA does not require data from such trials. Th e presentation will describe the essential elements of both the US and European preclinical and clinical testing procedures together with the outline of a testing programme that would be suitable for the global registration of a new CNS drug candidate.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Bioequivalence & Bioavailability.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Bioequivalence & Bioavailability
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “David Heal”